Skip to Main content Skip to Navigation
Journal articles

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model

Abstract : Around 40% of high-risk prostate cancer patients who undergo radiotherapy (RT) will experience biochemical failure. Chemotherapy, such as docetaxel (DTX), can enhance the efficacy of RT. Multidrug resistance mechanisms often limit drug efficacy by decreasing intracellular concentrations of drugs in tumor cells. It is, therefore, of interest to develop nanocarriers of DTX to maintain the drug inside cancer cells and thus improve treatment efficacy. The purpose of this study was to investigate the use of titanate nanotubes (TiONts) to develop a TiONts-DTX nanocarrier and to evaluate its radiosensitizing in vivo efficacy in a prostate cancer model. In vitro cytotoxic activity of TiONts-DTX was evaluated using an MTS assay. The biodistribution of TiONts-DTX was analyzed in vivo by single-photon emission computed tomography. The benefit of TiONts-DTX associated with RT was evaluated in vivo. Eight groups with seven mice in each were used to evaluate the efficacy of the nanohybrid combined with RT: control with buffer IT injection ± RT, free DXL ± RT, TiONts ± RT and TiONts-DXL ± RT. Mouse behavior, health status and tumor volume were monitored twice a week until the tumor volume reached a maximum of 2,000 mm3. More than 70% of nanohybrids were localized inside the tumor 96 h after administration. Tumor growth was significantly slowed by TiONts-DTX associated with RT, compared with free DTX in the same conditions (P=0.013). These results suggest that TiONts-DTX improved RT efficacy and might enhance local control in high-risk localized prostate cancer.
Complete list of metadata
Contributor : Julien Boudon Connect in order to contact the contributor
Submitted on : Tuesday, October 10, 2017 - 10:02:56 PM
Last modification on : Wednesday, November 3, 2021 - 8:12:36 AM


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Links full text



Céline Mirjolet, Julien Boudon, Alexis Loiseau, Sandy Chevrier, Romain Boidot, et al.. Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model. International Journal of Nanomedicine, Dove Medical Press, 2017, 12, pp.6357 - 6364. ⟨10.2147/IJN.S139167⟩. ⟨hal-01614449⟩



Record views